Clinical trials: Metastatic Renal Cancer
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Kidney Cancer
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer.
- Trial name
- NCT01217931
- Testing
- Pazopanib, Bevacizumab, Everolimus
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Non Clear Cell Renal Cell Carcinoma (nccRCC)
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
This is a single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus in participants with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any…
- Trial name
- NCT02915783
- Testing
- lenvatinib, everolimus
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eisai Inc.
Metastatic Renal Cell Carcinoma
MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.
- Trial name
- MRI (NCT00606866)
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Chicago
Anti-p53 TCR-Gene
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured…
- Trial name
- NCT00393029
- Testing
- anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Non-Clear Cell Renal Cell Carcinoma
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received…
- Trial name
- STELLAR-304 (NCT05678673)
- Testing
- XL092, Nivolumab, Sunitinib Malate
- Where
- 163 sites in United States, Argentina and 23 more
- Volunteers
- 317 people
- Sponsor
- Exelixis
Metastatic Renal Cell Carcinoma
Urine Omics Predicting IO Therapy Responses in mRCC Patients
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
- Trial name
- NCT04712305
- Testing
- No intervention required
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014274
- Testing
- carboplatin, gemcitabine hydrochloride, methotrexate
- Where
- 29 sites in Austria, Belgium and 9 more
- Volunteers
- 238 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 2A study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON ATLAS (NCT07870746)
- Testing
- 177Lu-TLX250
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Metastatic Renal Cell Carcinoma
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively.
- Trial name
- NCT05816642
- Testing
- sunitinib or pazopanib, PD-1 inhibitor combined with axitinib
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Kidney Cancer
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma.
- Trial name
- NCT00193154
- Testing
- OSI-774, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- SCRI Development Innovations, LLC
Stage IV Renal Cell Cancer AJCC V7
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
This study is designed as a phase-II proof of concept trial to investigate if a treatment strategy where stereotactic body radiation therapy (SBRT) is given with pembrolizumab is sufficiently active to warrant further…
- Trial name
- OZM-065 (NCT02599779)
- Testing
- Pembrolizumab, Stereotactic Body Radiation Therapy
- Where
- 3 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Sunnybrook Health Sciences Centre
Colorectal Cancer, Gastric Cancer
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive…
- Conditions
- Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05360680
- Testing
- CUE-102
- Where
- 15 sites in United States
- Volunteers
- 42 people
- Sponsor
- Cue Biopharma
Kidney Cancer
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00053820
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- 12 sites in Belgium, Germany and 2 more
- Volunteers
- 670 people
- Sponsor
- Medical Research Council
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy
The Effect of Etelcalcetide on CKD-MBD
The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and blood-vessels healthier.
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
- Trial name
- Parsabiv-MBD (NCT03960437)
- Testing
- Etelcalcetide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Thomas Nickolas, MD MS
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT05361720
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Kidney Cancer
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093405
- Testing
- tanespimycin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Neoplasms
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
- Trial name
- NCT00054886
- Testing
- SU-011,248
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.